Interval life events are an important determinant of heterogeneity in outcomes in a randomised trial: a novel, simple method of assessment.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
30 Jul 2024
Historique:
medline: 31 7 2024
pubmed: 31 7 2024
entrez: 30 7 2024
Statut: epublish

Résumé

Although life events are clearly important to health, most of the scientific focus has been on baseline life events that occur prior to a study. Life events that occur after enrolment, that is, interval life events, have had almost no attention. The aim of this analysis of data was to develop a method for measuring interval life events that could be used in clinical trials and other longitudinal studies. Small Changes and Lasting Effects (SCALE) was a 12-month weight-loss randomised controlled trial (RCT). This was an analysis of the SCALE follow-up data. Healthcare networks, outpatient clinics and community churches in the South Bronx and Harlem areas of New York City. Overweight black and Latino adults. This analysis focuses on the 330 of the 405 patients who had >4 weeks of follow-up with at least one perceived stress score (PSS). The SCALE RCT was published elsewhere and involved positive affect and self-affirmation to increase behaviour change. 5% weight loss. Over 12 months, up to 27 follow-ups were conducted that evaluated interval life events, eating and physical activity behaviour, weight and perceived stress. During these follow-ups, participants were asked two open-ended questions to capture interval life events. The interval life events were qualitatively coded into categories. The interval life events categories were compared with interval monthly measures of perceived stress using the 4-item PSS scale. During the interval follow-ups for the RCT, 70.6% of the 330 patients reported at least one interval life event, which occurred during a median of 15 follow-ups (95% CI: 5 to 24). The median number of interval events was 2 (95% CI: 0 to 8): 30.6% reported their own illness; 22%, death or bereavement; 21.8%, illness in the family and 13.1%, family conflicts. The mean perceived stress score (PSS-4) assessed over the year of follow-up was 3.2±2.7. Mean perceived stress (PSS-4) increased, especially for interval financial events, major conflict with a partner and unemployment, but by less for deaths, family illness and family conflict. Participants with the most interval life events had the greatest increase in interval perceived stress (p<0.0001). Of note, neither high baseline perceived stress (PSS-10 >20) nor baseline depression (Patient Health Questionnaire-9 >10) were associated with higher interval life events (p>0.05); but those with lower social support had more events. However, those with either depression or stress had higher interval stress responses. Most participants had neither baseline nor interval events, and the percentage with both was small so that baseline events did not predict subsequent perceived stress. This method provides a straightforward method of assessing interval life events, by asking two open-ended questions, that can be coded in a simple categorical framework. Such events can affect outcomes in longitudinal studies and trials in part by increasing perceived stress. This framework moves beyond the events identified as important in the 1950s and recognises that specific life events may have significantly different life impacts in different individuals. NCT01198990; Post-results.

Identifiants

pubmed: 39079918
pii: bmjopen-2023-074623
doi: 10.1136/bmjopen-2023-074623
doi:

Banques de données

ClinicalTrials.gov
['NCT01198990']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e074623

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Mary Charlson (M)

Medicine, Weill Cornell Medical College, New York City, New York, USA mecharl@med.cornell.edu.

Martin Wells (M)

Statistics and Data Science, Cornell University, Ithaca, New York, USA.

Carol M Devine (CM)

Cornell University, Ithaca, New York, USA.

Jerome Watts (J)

Howard University College of Medicine, Washington, District of Columbia, USA.

Rosio Ramos (R)

Medicine, Weill Cornell Medical College, New York City, New York, USA.

James Hollenberg (J)

Medicine, Weill Cornell Medical College, New York City, New York, USA.

Ginger Winston (G)

Office of New Drugs Division of Diabetes, FDA, Beltsville, Maryland, USA.

Erica Phillips (E)

Medicine, Weill Cornell Medical College, New York City, New York, USA.

Elaine Wethington (E)

Departments of Psychology and of Sociology, Cornell University, Ithaca, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH